Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02387203
Other study ID # MMC-2014-53
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date January 2015
Est. completion date December 2024

Study information

Verified date March 2023
Source Mercy Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the impact of antibiotic therapy on the disease progression and overall survival of patients with Pseudomyxoma Peritonei (PMP).


Description:

Single center, open label, historical controlled, phase II study that proposes two courses of standard H. Pylori eradication antibiotic therapy can suppress carcinogenesis and improve the long-term outcomes of patients with PMP. The first course of antibiotics (PrevPac) will be administered before cytoreductive surgery and HIPEC and the second course afterwards. The historical control group will consist of all PMP patients from Mercy Medical Center's Tumor Registry who did not receive perioperative antibiotic treatment. Long-term statistical outcomes will be calculated using the Kaplan-Meier method and Cox proportional hazard ratio to compare pertinent variable. 80 subjects to be enrolled over 2 years, with a 5 year follow-up period.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Patients must have measurable pseudomyxoma peritonei from appendiceal origin, confirmed by histology, cytology, or radiographical evidence - - Age = 21 years - Eastern Cooperative Oncology Group (ECOG) performance status score=2/Karnofsky performance status of (KPS) = 70% (see Appendix B) - Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) =1,000/mm3 Platelets =100,000/mm3 Hemoglobin = 8.5 g/dL Renal function: Creatinine =1.5 times the upper limit of normal (ULN) or calculated creatinine clearance =60ml/min Hepatic function: Bilirubin =1.5 times ULN Alanine aminotransferase (ALT) =3 times ULN Aspartate aminotransferase (AST) =3 times ULN - Ability of subject or Legally Authorized Representative (LAR) to understand and willingness to sign a written informed consent, approved by Mercy Medical Center Institutional Review Board (IRB) - A negative pregnancy test for women of childbearing age with all reproductive organs intact Exclusion Criteria: - Patients receiving any other investigational agents - Presence of other invasive malignancies or evidence of another cancer present within the last 3 years, excluding skin cancer - history of, or known allergic reaction/hypersensitivity to PREVPAC or any component of similar chemical or biologic composition to PREVPAC - Patients < 21 of age - Pregnancy or lactation at the time of proposed assignment. Pregnant women are excluded from this study because PREVPAC is based on the pregnancy category for clarithromycin which is Category C agent with the potential for teratogenic or abortifacient effects. These potential risks may also apply to CRS/HIPEC. - Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol (e.g., unable to swallow pills) - Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or giving informed consent - Known active acute hepatitis and confirmed diagnosis of Human Immunodeficiency Virus (HIV) infection. HIV-positive patients on combination antiretroviral therapy are ineligible. These patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. - Active systemic infection that requires use of parenteral antibiotics - Renal insufficiency with serum creatinine level =1.5 times the upper limit of normal or calculated - - Patients with concurrent severe medical problems unrelated to malignancy that will preclude compliance with the study or places at an unacceptable risk for participation in the study determinate by study investigators - Patients to be maintained on any medication having severe interactions with PREVPAC

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PrevPac (Prevacid, Amoxicillin, Clarithromycin)
30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively

Locations

Country Name City State
United States Mercy Medical Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Mercy Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Tolerance and safety of PrevPac administration Rate of morbidity and mortality Through 14 day treatment therapy
Other Analyze number of live bacteria in PMP tumor and mucin In situ hybridization [ISH], either bright light or fluorescence in situ hybridization [FISH] through study completion, an average of 5 years
Primary Overall survival Kaplan-Meier survival estimates 5 year
Secondary Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease Kaplan-Meier survival estimates 5 year
See also
  Status Clinical Trial Phase
Recruiting NCT04024917 - Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis N/A
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Active, not recruiting NCT01427101 - Results of CRS and Debulking in PMP Patients N/A
Active, not recruiting NCT04982146 - Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei Phase 1
Completed NCT04088786 - Phase I Trial HIPEC With Nal-irinotecan Phase 1
Not yet recruiting NCT06084780 - Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Phase 2
Active, not recruiting NCT02834169 - French National Registry of Rare Peritoneal Surface Malignancies N/A
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Withdrawn NCT04125225 - What Are the Experiences of Patients With Pseudomyxoma Peritonei?
Not yet recruiting NCT03976973 - BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Phase 2
Recruiting NCT01617382 - Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Completed NCT05513183 - Severe Neutropenia After HIPEC Using Mitomycin-C
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Terminated NCT04665921 - A Study of SGN-STNV in Advanced Solid Tumors Phase 1
Recruiting NCT05321329 - Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Phase 2